Khelik Imal A, Berger Darren J, Mochel Jonathan P, Seo Yeon-Jung, Palerme Jean-Sébastien, Ware Wendy A, Ward Jessica L
Am J Vet Res. 2019 Aug;80(8):743-755. doi: 10.2460/ajvr.80.8.743.
To evaluate the clinicopathologic, hemodynamic, and echocardiographic effects of short-term administration of anti-inflammatory dosages of prednisolone to systemically normal cats.
10 cats with allergic dermatitis and 10 healthy control cats.
Cats with allergic dermatitis were randomly allocated to 2 groups and received 2 dosages of prednisolone (1 and 2 mg/kg/d, PO, for 7 days) in a crossover design followed by 9-day tapering and 14-day washout periods. Each prednisolone-treated cat was matched to a healthy control cat on the basis of sex, neuter status, age (± 1 year), and body weight (± 10%). Control cats received no treatment during the 35-day observation period. Clinicopathologic, echocardiographic, and hemodynamic variables were measured at baseline (day 0) and predetermined times during and after prednisolone administration and compared within and between the 2 treatment groups.
Prednisolone-treated cats had expected clinicopathologic alterations (mild increases in neutrophil and monocyte counts and serum concentrations of albumin, cholesterol, and triglycerides) but systolic arterial blood pressure; blood glucose, serum potassium, and cardiac biomarker concentrations; urinary sodium excretion; and echocardiographic variables did not differ significantly from baseline at any time. Statistically significant, albeit clinically irrelevant, increases in blood glucose and N-terminal pro-B-type natriuretic peptide concentrations were observed between baseline and the prednisolone pharmacokinetic steady state (7 days after initiation) only when the 2-mg/kg dosage was administered.
Results indicated short-term oral administration of anti-inflammatory dosages of prednisolone did not cause relevant hemodynamic, echocardiographic, or diabetogenic effects in systemically normal cats with allergic dermatitis.
评估给全身状况正常的猫短期给予抗炎剂量泼尼松龙后的临床病理、血流动力学及超声心动图效应。
10只患过敏性皮炎的猫和10只健康对照猫。
患过敏性皮炎的猫被随机分为2组，采用交叉设计接受2种剂量的泼尼松龙（1和2mg/kg/d，口服，共7天），随后为9天的减量期和14天的洗脱期。每只接受泼尼松龙治疗的猫根据性别、去势状态、年龄（±1岁）和体重（±10%）与一只健康对照猫匹配。对照猫在35天的观察期内未接受治疗。在基线期（第0天）以及泼尼松龙给药期间和给药后的预定时间测量临床病理、超声心动图和血流动力学变量，并在2个治疗组内及组间进行比较。
接受泼尼松龙治疗的猫出现了预期的临床病理改变（中性粒细胞和单核细胞计数轻度增加，血清白蛋白、胆固醇和甘油三酯浓度升高），但收缩动脉血压、血糖、血清钾和心脏生物标志物浓度、尿钠排泄以及超声心动图变量在任何时候与基线相比均无显著差异。仅在给予2mg/kg剂量时，在基线期和泼尼松龙药代动力学稳态（开始给药后7天）之间观察到血糖和N末端B型利钠肽原浓度有统计学意义但临床无关的升高。
结果表明，给患过敏性皮炎的全身状况正常的猫短期口服抗炎剂量的泼尼松龙不会引起相关的血流动力学、超声心动图或致糖尿病效应。
